New York State Medicaid broadens insurance coverage for TMS therapy, incorporating NeuroStar® Advanced Therapy, for the treatment of major depressive disorder.
In a significant development for mental health treatment, Neuronetics, Inc., a leading medical technology company specialising in neurohealth disorders, announced that its flagship product, the NeuroStar Advanced Therapy, will be covered by New York Medicaid starting October 1, 2025, for fee-for-service Medicaid members, and November 1, 2025, for those enrolled in Medicaid Managed Care Plans.
NeuroStar Advanced Therapy is a non-drug, non-invasive treatment option for Major Depressive Disorder (MDD) that delivers targeted magnetic pulses to stimulate neurons in the brain. This innovative approach has proven effective in treating MDD, as shown by a large registry of patients with MDD treated with Transcranial Magnetic Stimulation, discussed in a study by Sackeim HA, et al.
The coverage expansion comes at a time when the prevalence and national burden of treatment-resistant depression and MDD in the United States is a pressing issue. According to a study published in the Journal of Clinical Psychiatry, an estimated 6.4 million people in the U.S. are unable to tolerate or receive inadequate relief from antidepressant medication.
For those struggling with treatment-resistant depression and MDD, Greenbrook treatment centers operated by Neuronetics offer SPRAVATO (esketamine) Nasal Spray, a prescription medicine for treatment-resistant depression (TRD) and depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
The NeuroStar Outcomes Database indicates that patients can achieve up to an 83% response rate and 62% remission rate of their MDD with NeuroStar Advanced Therapy. However, it's important to note that the effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated.
Neuronetics is the maker of NeuroStar Advanced Therapy and is the leading provider of Transcranial Magnetic Simulation (TMS). The company is also uniquely positioned in the industry, with a dedicated health policy team that partners with both providers and payors to advocate for health policy updates.
For more information about Neuronetics, Inc., please contact EvolveMKD at 646.517.4220 or [email protected]. For more details about New York Medicaid's TMS coverage, visit https://www.health.ny.gov/health_care/medicaid/program/update/2025/no07_2025-07.htm#TMS.
For important safety information about SPRAVATO, please visit spravatohcp.com. If you or someone you know is experiencing suicidal thoughts, please seek immediate help by calling the National Suicide Prevention Lifeline at 1-800-273-TALK (8255) or texting the Crisis Text Line at HOME to 741741.
This development marks a significant step forward in making effective mental health treatments more accessible to those who need them most.
Read also:
- Abu Dhabi initiative for comprehensive genetic screening, aiming to diagnose over 800 conditions and enhance the health of future generations in the UAE.
- Elderly shingles: Recognizing symptoms, potential problems, and available treatments
- Protecting Your Auditory Health: 6 Strategies to Minimize Noise Damage
- Exploring the Reasons, Purposes, and Enigmas of Hiccups: Delving into Their Origins, Roles, and Unsolved Aspects
